drugset

drugset / Trial / NCT07149363

Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer

NCT07149363 ↗

Phase 2 Recruiting 65 enrolled Alliance Foundation Trials, LLC. AstraZeneca · collab

NaSingle-groupOpen-labelTreatment

Summary

This is a phase II trial of adjuvant chemotherapy and immunotherapy for completely resected small cell lung cancer (SCLC).

Timeline

Start: 2026-02-12
Primary completion: 2029-02
Completion: 2031-02

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Durvalumab	Monoclonal antibody	1500 mg	—

Indications